St. Jude Children's Research Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, St. Jude Children's Research Hospital sits in the top decile of US sponsors by registered trial count (#87 of 15,742 sponsors by registered trial count).
St. Jude Children's Research Hospital: 410 sponsored US clinical trials, 90 recruiting.
St. Jude Children's Research Hospital sponsors 410 registered US clinical trials on ClinicalTrials.gov, 90 of them currently recruiting, and 227 completed. 19 of these trials are in Phase 3-4 (later-stage) and 173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sickle Cell Disease, with 17 trials.
Top-decile sponsor footprint
St. Jude Children's Research Hospital ranks in the top decile of sponsors by registered trial count (#87 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
227 of 259 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
410 total, page 5 of 9
Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma
NCT02792036
Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors
NCT02301065
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
NCT02846038
Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia With Down Syndrome
NCT02859389
Genetic Study of Families With High Frequency of Hodgkin Lymphoma
NCT02795013
Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma
NCT02747576
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02676323
First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor
NCT02661373
Bereaved Parent Study
NCT02425787
Medical Treatment Decision Making Using Adaptive Conjoint Analysis
NCT02608307
iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy
NCT02564484
Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children
NCT02649192
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT03071276
Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients
NCT02464098
Impact of Resistance Training-Protein Supplementation on Lean Muscle Mass in Childhood Cancer Survivors
NCT02501460
Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed With Solid Tumors: A Pilot Study
NCT02429063
Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas
NCT02415816
Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis
NCT02458937
Assessing Blood Pressure Remotely in Childhood Cancer Survivors
NCT02476162
Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia
NCT02473523
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
NCT02433483
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
NCT02419755
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
NCT02270788
A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents
NCT02352389
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
NCT02392793
Lactation Outcomes Among Survivors of Pediatric Cancer
NCT02399956
Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
NCT02336282
Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
NCT02193724
Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci
NCT02241005
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
NCT02130869
A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease
NCT02261480
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
NCT02259348
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
NCT02227472
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
NCT02212561
Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody
NCT02159443
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
NCT02199041
The Good Patient Study
NCT02199548
Incentives to Promote Medication Adherence Among HIV-Infected Youth
NCT02206906
Medication Adherence in Youth With Sickle Cell Disease (SCD)
NCT02143076
Medication Adherence in Human Immunodeficiency Virus (HIV)
NCT02119390
A Qualitative Case Study of the Experiences of Children With Cancer as They Learn About Their Diagnosis and Treatment
NCT02041689
Vascular Assessment in Adult Survivors of Childhood Cancer
NCT02010190
Transfusional Iron Overload Among Leukemia Survivors
NCT01965171
Pain Management in Children and Young Adults With Sickle Cell Disease
NCT01954927
Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease
NCT01959958
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
NCT01900509
Evaluating Rewards-Based Adherence and Electronic Medication Monitoring in HIV-Positive Adolescents
NCT01849393
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
NCT01807611
Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
NCT01820117
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
NCT01700946
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 86 |
| Phase 3 | 17 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the St. Jude Children's Research Hospital pipeline
90 recruiting of 410 indexed (22% open); 227 completed (55%).
Phase mix: 19 late (III/IV) vs 173 early (I/II) (early-phase heavy).
Top condition: Sickle Cell Disease (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
St. Jude Children's Research Hospital: open-pipeline peers nationwide
Peers matched on 410 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
St. Jude Children's Research Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 410 trials (± recruiting share)
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Rutgers, The State University of New Jersey · 413 trials · 26% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Northwell Health · 22% recruiting · 370 trials
- Vanda Pharmaceuticals · 22% recruiting · 68 trials
- Boston University Charles River Campus · 22% recruiting · 104 trials
- Regeneron Pharmaceuticals · 22% recruiting · 280 trials
Related
What to do with this St. Jude Children's Research Hospital page
410 registered trials is a research-attention snapshot, not an endorsement of St. Jude Children's Research Hospital or any single study.
- 90 of St. Jude Children's Research Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sickle Cell Disease is the condition St. Jude Children's Research Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sickle Cell Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
St. Jude Children's Research Hospital pipeline card: 410 registered trials from official public datasets.Report a data error.